Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04219982 · ClinicalTrials.gov registry record · Phase 2
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
A Phase 2 study, sponsored by Repurposed Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04219982 is a Phase 2 study that was terminated before completion, run by Repurposed Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT04219982, a Phase 2 study, was terminated before completion, sponsored by Repurposed Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Determine the efficacy, in terms of time to nausea (inclination to vomit), of DPI-386 Nasal Gel as compared to the current standard of care (TDS) and placebo nasal gel. • Describe the pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel (0.2 mg twice a day for six consecutive days) as compared to the current standard of care (TDS). Determine the safety of a multi-dose schedule of DPI-386 Nasal Gel with an emphasis on cognitive adverse events as compared to the current standard of care (TDS) and placebo nasal gel. Determine how alertness is affected by administration of DPI-386 Nasal Gel, as compared to the current standard of care (TDS) and placebo nasal gel.
Interventions
- DRUG DPI-386 Nasal Gel
- DRUG Transderm Scop®
- DRUG DPI-386 Placebo Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04219982
The ClinicalTrials.gov registry entry for NCT04219982 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DPI-386 Nasal Gel is the first listed.
NCT04219982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04219982 about?
NCT04219982 is a clinical study titled "DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness". Determine the efficacy, in terms of time to nausea (inclination to vomit), of DPI-386 Nasal Gel as compared to the current standard of care (TDS) and placebo nasal gel. • Describe the pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel (0.2 mg twice a day for six consecutive days) as...
What is the current status of trial NCT04219982?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-06-29. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT04219982?
The interventions under investigation include: DPI-386 Nasal Gel (DRUG), Transderm Scop® (DRUG), DPI-386 Placebo Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT04219982?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.